Arthneeti

FDC Q2 FY27 Share Price & Earnings Call Analysis

₹372.10-4.69% today
Market cap
₹6,058 Cr
P/E
18.44
ROE
11.46%
PEG
1.44
Price to sales
2.64
Debt to equity
0.00
52W high / low
₹434 / ₹321
Sales growth (5Y)
10.28%
EBITDA margin
15.98%
Net profit margin
12.58%
Promoter holding
69.65%
Sales (last year)
₹2,289 Cr

FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). .[1]

Guidance scorecard · Q2 FY27 call

What FDC's management guided
and where it ranks in Pharmaceuticals & Biotechnology

Revenue10–20%MarginsFlatCapexPlannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ2 FY24 call

10–20%
  • Domestic business growth is expected to continue with focus on volume, price, and new product mix, despite recent volume stagnation; price growth was 4.9% and new product growth 0.8% in H1 FY24.
  • Export business shows strong momentum with 25% Y-o-Y growth, reaching INR400 crores run rate; expected to grow further with increasing geographic spread.
  • No aggressive expansion of MR (Medical Representative) force planned; focus is on improving MR productivity and consolidating existing field force of ~4,800.
  • Growth drivers include expansion into weaker geographies like East and South India, along with strengthening top brands beyond INR100 crore mark.
  • Growth rate for FDC outpaced industry with 14.5% vs. market growth around 9-10% in recent months.

2 more points from FDC's call on revenue

Create a free account to keep reading this call

Full Q2 FY24 analysis

MarginsQ2 FY24 call

Flat

See what FDC said on margins — free account, 30 seconds.

Full Q2 FY24 analysis

CapexQ2 FY24 call

Planned
  • Ongoing capex includes construction of a new corporate office and R&D center, expected to complete by end of calendar year 2024, with expenditures spilling over into FY25.
  • Regular maintenance capex is around INR 50 crores annually.
  • Total capex for the next 12-15 months is approximately INR 170 crores, covering corporate office, manufacturing site projects, and smaller ongoing initiatives.
  • No major new R&D capital expenditure planned; focus is on revenue expenditure like clinical studies and regulatory filings, primarily for export markets (especially the US).

2 more points from FDC's call on capex

Create a free account to keep reading this call

Full Q2 FY24 analysis

FundraisingQ2 FY24 call

See what FDC said on fundraising — free account, 30 seconds.

Full Q2 FY24 analysis

Order bookQ2 FY24 call

Ask what FDC said on the order book →

Full Q2 FY24 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does FDC rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

FDC latest results (Sep 2026)

Revenue

₹572 Cr

+21% YoY

Net profit

₹49 Cr

+75% YoY

Operating margin

11%

EPS

₹3.01

What management said on the call →

FDC shareholding (Sep 2026)

Promoters

69.65%

unchanged QoQ

FIIs

1.57%

+0.17 pp QoQ

DIIs

6.59%

+0.28 pp QoQ

Public

22.17%

−0.46 pp QoQ

Full shareholding pattern →Dividend history →

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹3,041 Cr33.1
240%+Up 2%+₹492 Cr19.6
340%+Up 0–2%₹234 Cr17.8
440%+Flat₹18,347 Cr—
540%+Flat₹8,432 Cr32.4
640%+Flat₹4,295 Cr—

Sign up free to see every company in the sector ranking and track FDC.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

FDC announcements

All announcements →

Financials of FDC

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

FDC

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +69.66%69.66%69.66%69.66%69.66%69.66%69.66%69.66%69.66%69.65%69.65%69.65%
FIIs +2.43%2.65%2.51%2.62%2.67%2.56%2.41%2.43%2.32%2.40%1.40%1.57%
DIIs +7.76%6.94%6.72%6.02%6.08%6.37%7.17%6.81%6.27%6.29%6.31%6.59%
Public +20.15%20.76%21.11%21.71%21.60%21.42%20.76%21.10%21.76%21.65%22.63%22.17%
No. of Shareholders55,34152,37750,63455,40055,22853,88054,44554,15753,78852,73055,04554,621

Financials of FDC

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +486458462638514464492648473465585668572
Expenses +410374406492444417438508439412478525508
Operating Profit768456147704754140345210614364
OPM %16%18%12%23%14%10%11%22%7%11%18%21%11%
Other Income +2725202835191636210504818
Interest1111111111211
Depreciation10101011141316151515141516
Profit before tax939865163905153160383614017565
Tax %25%19%29%27%20%28%27%24%26%22%26%24%25%
Net Profit +707946119723739121282810313249
EPS in Rs4.294.872.847.314.422.282.387.451.741.746.358.143.01

Financials of FDC

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +8889941,0131,0741,0891,3411,3311,5251,7841,9432,1082,1712,289
Expenses +6907657698418601,0389971,2711,5331,6041,7831,8251,923
Operating Profit199229243233229304334254251339325346366
OPM %22%23%24%22%21%23%25%17%14%17%15%16%16%
Other Income +4639444542579576501029193116
Interest2111133344554
Depreciation39343535333738373940545960
Profit before tax204232252241237320388289258396357375417
Tax %27%27%25%28%28%25%22%25%25%23%25%25%
Net Profit +148169189174170240301216194305267281313
EPS in Rs8.339.4810.609.959.7414.0317.8512.8211.7018.7516.3917.2919.24
Dividend Payout %27%24%21%0%0%6%0%0%0%0%31%29%

Financials of FDC

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital18181818181717171716161616
Reserves9191,0651,2521,2591,4281,5301,7171,9401,9652,0812,2652,4692,653
Borrowings +211111515322821211513
Other Liabilities +210182197228194250208281333350412418494
Total Liabilities1,1481,2661,4681,5051,6401,8131,9562,2702,3432,4682,7142,9193,176
Fixed Assets +3936756786746826746897056996808529991,039
CWIP292061312241910519826113796163
Investments4893254914715856657908868068431,0281,0481,204
Other Assets +237246293348360451458575640684698775769
Total Assets1,1481,2661,4681,5051,6401,8131,9562,2702,3432,4682,7142,9193,176

Financials of FDC

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +128174154150112250207162155221318200
Cash from Investing Activity +-89-73-14421-121-98-77-14511-17-199-110
Cash from Financing Activity +-48-970-169-0-142-129-10-180-202-92-93
Net Cash Flow-94111-81017-14226-3
Free Cash Flow83-13013011470247148354715122740
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit96%101%92%94%81%110%90%95%93%96%129%83%

Financials of FDC

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days252327282934302025221926
Inventory Days132134148166184180189210183216186182
Days Payable94848110182101689499103102106
Cash Conversion Cycle64729493131113152135109135103102
Working Capital Days112123294540484548533341
ROCE %21%22%21%19%17%21%22%15%13%18%16%15%

Guidance history

How FDC's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q2 FY24 call →10–20%FlatPlanned——
Q1 FY23 call →10–20%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

25out of 100

Momentum score · price trend

25 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,937 stocks
Last 12 months−9.3%42%
Last 6 months+1.6%48%
Last 3 months+5.1%71%

The price is 37.7% below its all-time high of ₹596.85 (13 Sept 2024). Stocks more than 20% below their peak have their score halved, so 50 became 25.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,937 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For FDC: 0.4 × 42 + 0.4 × 48 + 0.2 × 71 = 50, halved to 25 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 13 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

FDC: frequently asked questions

What is FDC share price today?

FDC last traded at ₹372.1, with a market capitalisation of ₹6,058 Cr and a P/E ratio of 18.4.

What were FDC's latest quarterly results?

For the quarter ended Sep 2026, FDC reported revenue of ₹572 Cr (+21% year on year) and net profit of ₹49 Cr, with an operating margin of 11%.

Is FDC's profit growing?

Net profit was ₹49 Cr in Sep 2026 against ₹28 Cr in Sep 2025, a change of +75%.

What is FDC's EPS?

FDC's earnings per share for the quarter ended Sep 2026 was ₹3.01.

What is the promoter holding in FDC?

Promoters held 69.65% of FDC in Sep 2026 (unchanged versus Jun 2026).

How much do FIIs and DIIs hold in FDC?

In Sep 2026, foreign institutional investors held 1.57% and domestic institutions (including mutual funds) held 6.59% of FDC.

What is FDC's ROE and ROCE?

FDC's return on equity is 11.2% and its return on capital employed is 15.4%.

Does FDC pay a dividend?

Yes. FDC's dividend yield is 1.33% at the current price. The full payout history is on the FDC dividends page.

Which sector does FDC belong to?

FDC is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.

What did FDC's management say on the latest earnings call?

Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from FDC's management.

How does Arthneeti AI analyse FDC?

Arthneeti reads FDC's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.

Continue your research

What FDC's management said in earlier quarters

Earlier calls (6)

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q2 FY27)

    11.67% increase. Key results statement takeaways from Natural Capsules Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Sotac Pharmaceuticals (Q2 FY27)

    7,654.95 lakhs; Operating margin ≈ 10.68% for HY Sep 2026 . Key results statement takeaways from Sotac Pharmaceuticals Ltd's Q2 FY27 results statement — and how

  • Bio Medica Lab (Q2 FY27)

    EBITDA for the quarter:** ₹510 lakhs, up 25% year-on-year (YoY). Key results statement takeaways from Bio Medica Laboratories Ltd's Q2 FY27 results statement —

  • Syncom Formulations (India) (Q2 FY27)

    Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026):** ₹14,821.08 lakhs (Unaudited) . Key results statement takeaways from Syncom Formulations (India) Ltd's Q2 F